SuperworthLigand Pharmaceuticals profit margin LGND
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 67.9%
- Operating margin, 12 months
- 32.6%
- Net margin on a year earlier
- +108.3 pts
- Peer median
- 8.1%
Over the twelve months to Jun 30, 2026, Ligand Pharmaceuticals kept 67.9% of its revenue as net profit, with an operating margin of 32.6% and a gross margin of 95.4%.
Five years earlier its net margin was 20.2%.
The median for 10 large drugmakers of a similar size is 8.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 46.4% | 15.3% | 94.6% |
| FY2024 | −2.4% | −13.5% | 93.4% |
| FY2023 | 39.7% | 9.1% | 92.0% |
| FY2022 | −17.0% | 1.5% | 73.1% |
| FY2021 | 23.7% | 32.7% | 89.0% |
| FY2020 | −1.6% | 13.9% | 83.7% |
| FY2019 | n/a | n/a | 90.6% |
| FY2018 | 57.0% | 65.1% | 97.5% |
| FY2017 | 8.9% | 48.2% | 96.2% |
| FY2016 | −1.5% | 40.3% | 94.9% |
| FY2015 | n/a | 38.0% | 91.9% |
| FY2014 | 18.6% | n/a | n/a |
| FY2013 | 23.3% | 30.5% | 88.3% |
| FY2012 | −1.7% | 0.6% | 88.5% |
| FY2011 | 32.3% | −2.3% | 83.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 67.9% | +108.3 pts | 32.6% | |
| Q1 FY26 | 55.9% | +129.0 pts | 34.5% | |
| Q4 FY25 | 46.4% | +48.8 pts | 15.3% | |
| Q3 FY25 | 19.3% | −10.3 pts | 7.0% | |
| Q2 FY25 | −40.4% | −72.0 pts | −18.3% | |
| Q1 FY25 | −73.1% | −154.5 pts | −34.1% | |
| Q4 FY24 | −2.4% | −42.1 pts | −13.5% | |
| Q3 FY24 | 29.7% | +19.0 pts | −10.7% | |
| Q2 FY24 | 31.6% | +16.5 pts | −12.3% | |
| Q1 FY24 | 81.4% | +69.7 pts | 0.6% | |
| Q4 FY23 | 39.7% | +56.7 pts | 9.1% | |
| Q3 FY23 | 10.7% | +21.3 pts | −3.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| LGNDLigand Pharmaceuticals | 67.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| ALKSAlkermes plc. | 4.0% |
| TGTXTG Therapeutics | 55.2% |
| PTGXProtagonist Therapeutics | 29.4% |
| INDVIndivior Pharmaceuticals | 26.7% |
| CORTCorcept Therapeutics | 6.6% |
| ARQTArcutis Biotherapeutics | 6.1% |
| LQDALiquidia | 30.7% |
| OGNOrganon | 3.4% |
| Peer median | 8.1% |
Where Ligand Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Ligand Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.